VCYT stock forecast
Our latest prediction for Veracyte, Inc.'s stock price was made on the Sept. 10, 2019 when the stock price was at 25.12$.
In the short term (2weeks), VCYT's stock price should outperform the market by 1.15%. During that period the price should oscillate between -6.28% and +8.12%.
In the medium term (3months), VCYT's stock price should outperform the market by 5.87%. During that period the price should oscillate between -13.83% and +24.92%.Get email alerts
About Veracyte, Inc.
Veracyte, Inc. engages in the research, development, and commercialization of diagnostic products. Its portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.
At the moment the company generates 109M USD in revenues.
On its last earning announcement, the company reported a loss of -0.27$ per share.
The book value per share is 0.75$
Three months stock forecastSept. 10, 2019
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|